Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Sotlar

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
European Journal of Clinical Investigation|December 22, 2006
Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cellsA W Hauswirth, S Florian, D Printz, et al.
Prostate Cancer and Prostatic Diseases|January 11, 2012
ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodiesM Braun, D Goltz, D Adler, et al.
Der Urologe. Ausg. A|August 19, 2007
[The interdisciplinary approach to improve treatment quality of prostate cancer. Optimized nerve sparing in radical prostatectomy]K-D Sievert, A G Anastasiadis, J Hennenlotter, et al.
Annals of Hematology|November 19, 2013
Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosisSigrid Machherndl-Spandl, W Sega, H Bösmüller, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|January 23, 2014
Predictors of clinical effectiveness of Hymenoptera venom immunotherapyF Ruëff, B Vos, J Oude Elberink, et al.
Leukemia|July 16, 2016
Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosisM Jawhar, J Schwaab, D Hausmann, et al.
Leukemia|January 9, 2015
Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late eventM Jawhar, J Schwaab, S Schnittger, et al.
Leukemia|October 15, 2015
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosisM Jawhar, J Schwaab, S Schnittger, et al.
Leukemia|January 17, 2017
Proposed diagnostic criteria and classification of basophilic leukemias and related disordersP Valent, K Sotlar, K Blatt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
Midostaurin: a magic bullet that blocks mast cell expansion and activationP Valent, C Akin, K Hartmann, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
European Journal of Clinical Investigation|December 22, 2006
Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cellsA W Hauswirth, S Florian, D Printz, et al.
Prostate Cancer and Prostatic Diseases|January 11, 2012
ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodiesM Braun, D Goltz, D Adler, et al.
Der Urologe. Ausg. A|August 19, 2007
[The interdisciplinary approach to improve treatment quality of prostate cancer. Optimized nerve sparing in radical prostatectomy]K-D Sievert, A G Anastasiadis, J Hennenlotter, et al.
Annals of Hematology|November 19, 2013
Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosisSigrid Machherndl-Spandl, W Sega, H Bösmüller, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|January 23, 2014
Predictors of clinical effectiveness of Hymenoptera venom immunotherapyF Ruëff, B Vos, J Oude Elberink, et al.
Leukemia|July 16, 2016
Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosisM Jawhar, J Schwaab, D Hausmann, et al.
Leukemia|January 9, 2015
Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late eventM Jawhar, J Schwaab, S Schnittger, et al.
Leukemia|October 15, 2015
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosisM Jawhar, J Schwaab, S Schnittger, et al.
Leukemia|January 17, 2017
Proposed diagnostic criteria and classification of basophilic leukemias and related disordersP Valent, K Sotlar, K Blatt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
Midostaurin: a magic bullet that blocks mast cell expansion and activationP Valent, C Akin, K Hartmann, et al.
Pageof 6